TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02626494

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 14 days before or after, placebo will be administered analogously as described with n-AC. Placebo will be given according to a double-blind, placebo-controlled cross-over design. Subjects receive 3 doses of placebo over 2 consecutive days (total dose=4800mg; individual doses=2x1200mg, 1x2400mg). Subjects will take 2 first doses (à 1200mg) of placebo 1 day before scanning (one in the morning, one in the evening), and the last dose (2400mg) 1h prior to scanning, with 12 hours dosing intervals in between. Preparation and blinding of placebo capsules will be performed by the Kantonsapotheke Zürich according to the guidelines of Good Manufacturing Practice.
Study: NCT01697956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDP
Description: Beclomethasone dipropionate (BDP) 80 mcg/day (40 mcg/spray, 1 spray/nostril, once daily - total 2 sprays/day) as a nasal aerosol.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (1 spray/nostril, once daily - total 2 sprays/day) as a nasal aerosol.
Study: NCT03842228

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib Hydrochloride
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study: NCT01681511

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ICET™ TIC Foley Catheter
Description: The device to be evaluated in this investigation is a silver-based antimicrobial coated Foley catheter connected to an antimicrobial anti-reflux accessory (ICET Inc, Norwood, MA). The closed system is referred to as the TIC system and is designed with the objective of reducing the incidence of CAUTI. The accessory is non-tissue contacting.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BARD® LUBRI-SIL® IC Foley Catheter
Description: The LUBRI-SIL® I.C. antimicrobial 100% silicone Foley catheter incorporates a formulation consisting of BACTI-GUARD®\* silver alloy coating and BARD® hydrogel.
Study: NCT03842228

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo x-ray
Study: NCT01496313

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 300mg vandetanib
Description: Oral blinded tablets taken once daily.~At objective disease progression or 14 months (whichever is earlier), patient may be unblinded to treatment~Dosing with unblinded study treatment can continue until 24 months after patient was randomised.~At any time dosing may be interrupted for up to 6 weeks due to toxicity. Dosing may restart at a reduced dose (200mg/day). Once reduced, dose increases are not permitted and dosing must stop if further toxicities occur.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 150mg vandetanib
Description: Oral blinded tablets taken once daily.~At objective disease progression or 14 months (whichever is earlier), patient may be unblinded to treatment. Patients who have not dose reduced at the time of unblinding may have their dose increased to 300mg~Dosing with unblinded study treatment can continue until 24 months after patient was randomised~At any time dosing may be interrupted for up to 6 weeks due to toxicity. Dosing may restart at a reduced dose (100mg/day) \[OR 300 reduced to 200mg/day if dose was increased at unblinding.\] Once reduced, dose increases are not permitted and dosing must stop if further toxicities occur.
Study: NCT03719092

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin A Compound
Description: Given PO or enterally

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care
Study: NCT03513627

Intervention type: PROCEDURE
Intervention: Post-occlusive reactive hyperemia test (PORH test)
Description: Compression is applied on the buccal side of the attached gingiva, perpendicular to the long axis of the natural or implant born crown 2 mm far from the gingival margin.

Intervention type: PROCEDURE
Intervention: Post-occlusive reactive hyperemia test (PORH test)
Description: Compression is applied on the buccal side of the attached gingiva, perpendicular to the long axis of the natural or implant born crown 2 mm far from the gingival margin.
Study: NCT03969927

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-Fidelity PDS
Description: The principal investigator recently developed a low cost ($10,000) low fidelity portable driving simulator (PDS) in the University of Kansas Laboratory for Advanced Rehabilitation Research in Simulation (LARRS) that measures 25.5 Wide, 32.5 High, and 25 Deep and requires only approximately 4 square feet of space.~This intervention uses the PDS to retrain study participants and improve their driving related skills.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Fidelity Fixed-Base Simulator
Description: This intervention uses the large high-fidelity fixed-base driving simulator to retrain study participants and improve their driving related skills.
Study: NCT04566432

Intervention type: OTHER
Intervention: Observation
Description: observe the association of ctDNA with efficacy of treatment

Intervention type: OTHER
Intervention: Observation
Description: observe the association of ctDNA with efficacy of treatment
Study: NCT03124082

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: continuous infusion intraop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: bolus 0,5 mg/kg + infusion 0,25 mg/kg/h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: lidocaine bolus 1 mg/kg + infusion 1 mg/kg/h
Study: NCT02233322

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron
Description: All subjects will receive iron supplementation based on iron levels in the blood
Study: NCT04542525

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACRYSOF IQ PanOptix Toric Trifocal IOL
Description: Single-piece, ultraviolet and blue-light filtering, foldable, multifocal toric IOL intended to provide vision to aphakic subjects at near, intermediate, and distance and to correct pre-existing corneal astigmatism

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Description: Cataract extraction by phacoemulsification, followed by implantation of the IOL per investigator's standard of care and instructions for use
Study: NCT03124082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: clonidine 4 mcg/kg
Study: NCT03993522

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Symptom limited cardiopulmonary exercise test & Sub-maximal cardiopulmonary exercise test
Description: Exercise tests on cycle ergometer for the purpose of collecting expired breath gasses
Study: NCT00068302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: 3-6 subjects will be enrolled into each dose level
Study: NCT03596684

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: citrulline supplementation
Description: 2.5 g per os of citrulline on the morning and the evening (5 g/ jour) during 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo supplementation
Description: 2.5 g of the product in the morning and in the evening during 4 weeks.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: glucose tolerance test
Description: 2 exploration mornings distant from 28 days (before and after citrulline) will allow carrying out an oral glucose tolerance test of 2 hours (75 g glucose per os)
Study: NCT02409966

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadrant-wise scaling
Description: Patients underwent quadrant scaling under local anesthesia in four weekly sections. Three experienced trained periodontists carried out debridement procedures of both protocols with manual Gracey and McCall curettes and Hirschfield files.~Oral hygiene instructions were given for all participants and oral supplies were provided for the duration of the study.
Study: NCT01524861

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a placebo tablet bis in die for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpha-lipoic acid
Description: alpha-lipoic, tablets of acid 400 mg bis in die (800 mg/day), for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-acetyl carnitine
Description: L-acetyl carnitine tablets, 500 mg bis in die (1000 mg/day), for 12 months
Study: NCT02409966

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Full-mouth 24-hour scaling
Description: Patients underwent full-mouth scaling under local anesthesia in two sections within 24 hours. Three experienced trained periodontists carried out debridement procedures of both protocols with manual Gracey and McCall curettes and Hirschfield files.~Oral hygiene instructions were given for all participants and oral supplies were provided for the duration of the study.
Study: NCT05720936

Intervention type: PROCEDURE
Intervention: Percutaneous stellate ganglion block (PSGB)
Description: Both the two approaches present in literature and commonly used for this technique are allowed for the study:~* The anatomical approach which consist in the identification of the Chassaignac's tubercle that represents the point of needle insertion~* The echo-guided approach
Study: NCT02136719

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bimanual uterine compression
Description: bimanual uterine compression immediately after delivery of placenta for 5 minutes
Study: NCT04420390

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Low-dose radiotherapy
Study: NCT03651011

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept Injection [Eylea]
Description: Intravitreal injection 2 mg Eylea every 4 weeks M0-M2 (loading phase). M3-M12: continue in a pro re nata treatment regimen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept Injection [Eylea]
Description: Intravitreal injection 2 mg Eylea every 4 weeks M0-M2 (loading phase). M3-M12: continue in a pro re nata treatment regimen.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Navigated laser photocoagulation
Description: Navigated laser photocoagulation planned from flourscein angiography.
Study: NCT02984228

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRP

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Study: NCT03753867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acitretin
Description: Acitretin will be provided to participants in the formulation Soriatane. Soriatane doses are oral tablets taken daily by the participant. Participants will then receive 35mg of oral acitretin (Soriatane) daily for 8 weeks during the intervention phase. Participants will be asked to return two months after completion of the acitretin course for clinical follow-up and additional phlebotomy for laboratory testing.
Study: NCT03049189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-edotreotide PRRT
Description: PRRT using 177Lu-edotreotide will be performed 3-monthly. A maximum of four cycles will be administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Everolimus will be adminstered as a standard dosis of 10 mg daily which may be reduced where required for acceptable tolerability.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amino-Acid Solution
Description: The Amino-Acid Solution (AAS) to be used in this study will contain a mixture of 25 g lysine and 25 g arginine diluted in 2000 mL of electrolyte solution, infused over 4 - 6 h, starting 30 - 60 min before PRRT
Study: NCT01329991

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PLX5622
Description: PLX5622 drug substance is an achiral,small molecule Fms kinase inhibitor. The drug product is available in capsule form, to be taken orally, in a dosage strength of 100 mg with matching placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PLX5622
Description: PLX5622 drug substance is an achiral,small molecule Fms kinase inhibitor. The drug product is available in capsule form, to be taken orally, in a dosage strength of 100 mg with matching placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PLX5622
Description: PLX5622 drug substance is an achiral,small molecule Fms kinase inhibitor. The drug product is available in capsule form, to be taken orally, in a dosage strength of 100 mg with matching placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PLX5622
Description: PLX5622 drug substance is an achiral,small molecule Fms kinase inhibitor. The drug product is available in capsule form, to be taken orally, in a dosage strength of 100 mg with matching placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for PLX5622
Study: NCT01917214

Intervention type: OTHER
Intervention: Sutent: Observational Study
Description: Sutent oral therapy
Study: NCT04359147

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Yohimbine
Description: Effects on neural correlates of decision-making under risk and selective attention to threat

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: Effects on neural correlates of decision-making under risk and selective attention to threat
Study: NCT05018065

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Women sexual dysfunctions were screened using Female Sexual Functioning Index (FSFI)
Description: sexual dysfunction assesment
Study: NCT02843035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venglustat (GZ402671)
Description: Pharmaceutical form: capsule~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imiglucerase
Description: Pharmaceutical form: sterile lyophilized product~Route of administration: intravenous
Study: NCT00130026

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Caffeine
Description: 500 mg IV
Study: NCT04553627

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ZELTIQ thermoelectric device
Description: This is a feasibility study to determine if cryolipolysis in this area produces a desirable lifted appearance to the buttocks. Typically, a lifted more youthful appearance is obtained through surgical means. Study participants will be recruited from the population of patients who have suitable, treatable subcutaneous fat on the medial infragluteal folds and desire a lifted appearance. Subjects will receive treatments with a cooled cup cryolipolysis applicator from the CoolAdvantage family of applicators (cooled cup vacuum applicator). Treatments will be performed with a treatment temperature of - 11°C for up to 35 minutes. Subjects will complete all study-required follow-up visits, including an 8-week follow-up which may include a second treatment session, as well as a 12-week post final treatment follow-up visit
Study: NCT02182362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 NA
Study: NCT03432871

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide Riboside
Description: Nicotinamide Riboside is a member of the Vitamin B family which acts as a precursor to NAD+, an enzyme involved in energy production.
Study: NCT02696109

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: Participants in the TAU arm will be assigned to standard care at our partnering mental health agency. These clients are free to attend one-on-one counseling or any other services available at the clinic or elsewhere to address mental health challenges.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cornerstone
Description: Participants in the experimental arm will be assigned a Transition Facilitator, a clinician with whom the client will meet one-on-one, and will be asked to attend once-a-week groups with other transition age youth. The groups will focus on issues relevant to successful transition to independent adulthood including stress and anger management and healthy relationships.
Study: NCT00438048

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pilocarpine
Description: or secondary symptomatic SS with clinically significant dry mouth were randomized to receive either 5 mg oral Pilocarpine solution (5ml) or artificial saliva (5 ml) 3 times a day for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artificial Saliva
Description: 5ml 3 times daily
Study: NCT02182362

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03463564

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insulin pump
Description: Continuous subcutaneous insulin infusion consisting of the delivery of insulin lispro as basal rate and boluses administered before meals.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin injections
Description: Four injections of insulin daily consisting in three bolus of a rapid-acting analog lispro or aspart before breakfast, lunch and dinner and one injection of insulin glargine or degludec at bed-time of basal insulin
Study: NCT01816828

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gay Poz Sex
Description: Gay Poz Sex is a community-driven, peer-facilitated program for HIV+ gay and bisexual men. This eight week program is offered to small groups of 5-8 men and provides information about sexual health, the legal context of HIV non-disclosure and uses motivational interviewing to support each individual in setting and achieving a personal goal.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wait List/Standard of Care
Description: Participants are given referrals to existing resources in the community. Referrals and uptake will be tracked.
Study: NCT00177970

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous immunoglobulin G (IVIG)
Description: IVIG to be given IV to patients with C-Diff .

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to be given IV to patients with C-Diff
Study: NCT04523233

Intervention type: DIAGNOSTIC_TEST
Intervention: Amniocentesis
Description: Amniocentesis is a procedure in which amniotic fluid is removed from the uterus for testing or treatment.

Intervention type: DIAGNOSTIC_TEST
Intervention: Amniocentesis
Description: Amniocentesis is a procedure in which amniotic fluid is removed from the uterus for testing or treatment.
Study: NCT02149173

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo F-18 FES PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo FDG PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 16 Alpha-Fluoroestradiol
Description: Undergo F-18 FES PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Undergo FDG PET/CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo F-18 FES PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FDG PET/CT
Study: NCT02858219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Indexes
Description: Visual Analogic Scale (VAS), Female Sexual Function Index (FSFI), Dermatology Life Quality Index (DLQI)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Indexes
Description: Visual Analogic Scale (VAS), Female Sexual Function Index (FSFI), Dermatology Life Quality Index (DLQI)
Study: NCT01463371

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: 250 mg three times a week during three months
Study: NCT02467556

Intervention type: DRUG
Group type: OTHER
Intervention: Morphine, memantine
Description: Morphine up to 30 mg per day orally and memantine up to 40 mg per day orally if tolerated for 10 weeks.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Psychological intervention
Description: To help patients shift perspective from pain and CRPS-symptoms, to increase body awareness, to create vivid imagenary, to increase the use of a CRPS hand with mindfulness exposure exercises, to increase flexibility in behavioral repertoire, to explore the fusion of emotions, automatic cognitions and learned responses and to help patients to integrate new skills in their lives.

Intervention type: OTHER
Group type: OTHER
Intervention: Physiotherapy intervention
Description: Graded motor imagenary with group and individual weekly sessions with daily practices at home.